Michel Vounatsos, Biogen CEO (via YouTube)
April 23, 2020 09:01 AM EDTUpdated April 24, 07:07 AM
People
Bioregnum
Opinion

Bio­gen’s top ex­ec­u­tive crew has a big cred­i­bil­i­ty is­sue. And they seem de­ter­mined to make it worse

First came the pan­dem­ic “su­per­spread­er” event at the Mar­riott Long Wharf that cre­at­ed a sim­mer­ing pub­lic re­la­tions night­mare for Bio­gen $BI­IB. And now here …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times